表紙
市場調查報告書

免疫血液學:醫療設備的開發平台評估

Immunohematology - Medical Devices Pipeline Assessment, 2019

出版商 GlobalData 商品編碼 666937
出版日期 內容資訊 英文 101 Pages
訂單完成後即時交付
價格
Back to Top
免疫血液學:醫療設備的開發平台評估 Immunohematology - Medical Devices Pipeline Assessment, 2019
出版日期: 2019年11月14日內容資訊: 英文 101 Pages
簡介

本報告提供全球免疫血液學相關市場上的主要開發中產品及其臨床實驗進展調查,並彙整產品的功能·特性比較分析 (臨床實驗的各進展階段) ,及主要企業·組織的簡介及代表性產品,近來的市場動靜 (業績報告·資本交易趨勢等) 資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 免疫血液學概要

第3章 臨床實驗中的產品

  • 開發中產品:各臨床實驗階段
  • 開發中產品:各領域
  • 開發中產品:各地區
  • 開發中產品:各法規途徑
  • 開發中產品:各估計認證時期

第4章 免疫血液學:臨床實驗中的開發中產品,各企業

  • 免疫血液學的企業:各臨床實驗階段的開發中產品
  • 免疫血液學:各臨床實驗階段的開發中產品

第5章 免疫血液學市場:企業·產品概要

  • AbSorber AB
  • Amity University
  • Arizona State University
  • Biofortuna Ltd
  • Grifols SA
  • Haemonetics Corp
  • Immucor, Inc.
  • Ortho-Clinical Diagnostics Inc
  • Quotient Limited
  • TBG Diagnostics Ltd
  • Transfusion & Transplantation Technologies (Inactive)

第6章 免疫血液學市場:目前的趨勢

第7章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0816EPD

GlobalData's Medical Devices sector report, "Immunohematology - Medical Devices Pipeline Assessment, 2019" provides an overview of Immunohematology currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Immunohematology pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Immunohematology under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Immunohematology and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Immunohematology under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

  • 1.1 List of Tables 4
  • 1.2 List of Figures 5

2 Introduction 6

  • 2.1 Immunohematology Overview 6

3 Products under Development 7

  • 3.1 Immunohematology - Pipeline Products by Stage of Development 7
  • 3.2 Immunohematology - Pipeline Products by Segment 8
  • 3.3 Immunohematology - Pipeline Products by Territory 9
  • 3.4 Immunohematology - Pipeline Products by Regulatory Path 10
  • 3.5 Immunohematology - Pipeline Products by Estimated Approval Date 11

4 Immunohematology - Pipeline Products under Development by Companies 12

  • 4.1 Immunohematology Companies - Pipeline Products by Stage of Development 12
  • 4.2 Immunohematology - Pipeline Products by Stage of Development 13

5 Immunohematology Companies and Product Overview 14

  • 5.1 AbSorber AB Company Overview 14
    • 5.1.1 AbSorber AB Pipeline Products & Ongoing Clinical Trials Overview 14
  • 5.2 Alba Bioscience Limited Company Overview 15
    • 5.2.1 Alba Bioscience Limited Pipeline Products & Ongoing Clinical Trials Overview 15
  • 5.3 Amity University Company Overview 17
    • 5.3.1 Amity University Pipeline Products & Ongoing Clinical Trials Overview 17
  • 5.4 Arizona State University Company Overview 18
    • 5.4.1 Arizona State University Pipeline Products & Ongoing Clinical Trials Overview 18
  • 5.5 Biofortuna Ltd Company Overview 19
    • 5.5.1 Biofortuna Ltd Pipeline Products & Ongoing Clinical Trials Overview 19
  • 5.6 Grifols SA Company Overview 24
    • 5.6.1 Grifols SA Pipeline Products & Ongoing Clinical Trials Overview 24
  • 5.7 Ortho-Clinical Diagnostics Inc Company Overview 25
    • 5.7.1 Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 25
  • 5.8 Quotient Ltd Company Overview 27
    • 5.8.1 Quotient Ltd Pipeline Products & Ongoing Clinical Trials Overview 27
  • 5.9 Transfusion & Transplantation Technologies (Inactive) Company Overview 30
    • 5.9.1 Transfusion & Transplantation Technologies (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 30

6 Immunohematology- Recent Developments 35

  • 6.1 Nov 04, 2019: Quotient reports second quarter fiscal 2020 financial results 35
  • 6.2 Nov 01, 2019: Haemonetics reports 2nd quarter and 1st half fiscal 2020 results; raises fiscal 2020 adjusted operating margin and adjusted EPS guidance 37
  • 6.3 Oct 31, 2019: Bio-Rad reports third-quarter 2019 financial results 39
  • 6.4 Oct 31, 2019: Bio-Rad reports third-quarter 2019 financial results. 40
  • 6.5 Oct 14, 2019: Biocare Medical appoints Nicolas Barthelemy as Executive Chairman 41
  • 6.6 Sep 24, 2019: Theradiag announces improved results for H1 2019 41
  • 6.7 Sep 12, 2019: Haemonetics Appoints Stewart W. Strong As President, Global Hospital 44
  • 6.8 Sep 11, 2019: Bio-Rad files new lawsuit against 10X Genomics for Patent Infringement 45
  • 6.9 Aug 29, 2019: Siemens Healthineers announces new Canadian leadership 45
  • 6.10 Aug 06, 2019: Haemonetics reports 1st Quarter Fiscal 2020 results, updates Fiscal 2020 earnings guidance and launches operational excellence program 46

7 Appendix 98

  • 7.1 Methodology 98
  • 7.2 About GlobalData 101
  • 7.3 Contact Us 101
  • 7.4 Disclaimer 101

List of Tables

  • Table 1: Immunohematology - Pipeline Products by Stage of Development 8
  • Table 2: Immunohematology - Pipeline Products by Segment 9
  • Table 3: Immunohematology - Pipeline Products by Territory 10
  • Table 4: Immunohematology - Pipeline Products by Regulatory Path 11
  • Table 5: Immunohematology - Pipeline Products by Estimated Approval Date 12
  • Table 6: Immunohematology Companies - Pipeline Products by Stage of Development 13
  • Table 7: Immunohematology - Pipeline Products by Stage of Development 14
  • Table 8: AbSorber AB Pipeline Products & Ongoing Clinical Trials Overview 15
  • Table 9: ABO Diagnostic Test - Product Status 15
  • Table 10: ABO Diagnostic Test - Product Description 15
  • Table 11: Alba Bioscience Limited Pipeline Products & Ongoing Clinical Trials Overview 16
  • Table 12: ALBAcyte O Adult i Cell Reagent - Product Status 16
  • Table 13: ALBAcyte O Adult i Cell Reagent - Product Description 16
  • Table 14: ALBAcyte O RhD VI Reagent Cells - Product Status 16
  • Table 15: ALBAcyte O RhD VI Reagent Cells - Product Description 17
  • Table 16: Amity University Pipeline Products & Ongoing Clinical Trials Overview 18
  • Table 17: Blood Group Testing Kit - Product Status 18
  • Table 18: Blood Group Testing Kit - Product Description 18
  • Table 19: Arizona State University Pipeline Products & Ongoing Clinical Trials Overview 19
  • Table 20: Blood Screening Immunosignaturing - Product Status 19
  • Table 21: Blood Screening Immunosignaturing - Product Description 19
  • Table 22: Biofortuna Ltd Pipeline Products & Ongoing Clinical Trials Overview 20
  • Table 23: HemoPlex Kell Genotyping Kit - Product Status 20
  • Table 24: HemoPlex Kell Genotyping Kit - Product Description 20
  • Table 25: HemoPlex Kidd & Duffy Genotyping Kit - Product Status 21
  • Table 26: HemoPlex Kidd & Duffy Genotyping Kit - Product Description 21
  • Table 27: HemoPlex MNS Genotyping Kit - Product Status 21
  • Table 28: HemoPlex MNS Genotyping Kit - Product Description 21
  • Table 29: HemoPlex Multi Blood Group Genotyping Kit - Product Status 22
  • Table 30: HemoPlex Multi Blood Group Genotyping Kit - Product Description 22
  • Table 31: HemoPlex RHCE Screening Kit - Product Status 22
  • Table 32: HemoPlex RHCE Screening Kit - Product Description 22
  • Table 33: HemoPlex RHCE Variant Genotyping Kit - Product Status 23
  • Table 34: HemoPlex RHCE Variant Genotyping Kit - Product Description 23
  • Table 35: HemoPlex RHD & CE Genotyping Kit - Product Status 23
  • Table 36: HemoPlex RHD & CE Genotyping Kit - Product Description 23
  • Table 37: HemoPlex RHD Variant Genotyping Kit - Product Status 24
  • Table 38: HemoPlex RHD Variant Genotyping Kit - Product Description 24
  • Table 39: ThromboPlex HPA Screening Kit - Product Status 24
  • Table 40: ThromboPlex HPA Screening Kit - Product Description 25
  • Table 41: Grifols SA Pipeline Products & Ongoing Clinical Trials Overview 26
  • Table 42: IH Blood Genotyping (D) Kit - Product Status 26
  • Table 43: IH Blood Genotyping (D) Kit - Product Description 26
  • Table 44: Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 27
  • Table 45: ORTHO AutoVue - Rare Sera Assay - Product Status 27
  • Table 46: ORTHO AutoVue - Rare Sera Assay - Product Description 27
  • Table 47: ORTHO BioVue - Rare Sera Assay - Product Status 28
  • Table 48: ORTHO BioVue - Rare Sera Assay - Product Description 28
  • Table 49: Quotient Ltd Pipeline Products & Ongoing Clinical Trials Overview 29
  • Table 50: Eluate Kit - Product Status 29
  • Table 51: Eluate Kit - Product Description 29
  • Table 52: Expanded IH Microarray - Product Status 30
  • Table 53: Expanded IH Microarray - Product Description 30
  • Table 54: IH Microarray Patient - Product Status 30
  • Table 55: IH Microarray Patient - Product Description 30
  • Table 56: Polyagglutionation Kit - Product Status 31
  • Table 57: Polyagglutionation Kit - Product Description 31
  • Table 58: Sensitivity Kit Anti-S, K, e, C - Product Status 31
  • Table 59: Sensitivity Kit Anti-S, K, e, C - Product Description 31
  • Table 60: Transfusion & Transplantation Technologies (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 33

List of Figures

  • Figure 1: Immunohematology - Pipeline Products by Stage of Development 7
  • Figure 2: Immunohematology - Pipeline Products by Segment 8
  • Figure 3: Immunohematology - Pipeline Products by Territory 9
  • Figure 4: Immunohematology - Pipeline Products by Regulatory Path 10
  • Figure 5: Immunohematology - Pipeline Products by Estimated Approval Date 11
Back to Top